10034129Improved In-Vitro Fertilisation (IVF) implantation success rate using advanced proteomic analysis of embryo culture fluid.ClosedCollaborative R&DInnovate UKInfertility affects one in seven couples in the UK. Endometriosis, polycystic ovaries, or ovulation disorders affect 20% of women, while male infertility is rising significantly. The WHO recognises infertility as a disease, and the devastation and grief it causes is widely acknowledged. The NHS provides limited IVF support for infertile couples but is cutting provision. Private clinics service the need but with multiple cycles usually required and a 25-30% success rate, the costs (£1,500 - £5,000 per cycle) and stress involved are extremely high. Embryos vary in quality, the best most likely to implant and lead to a pregnancy. Embryologists use training and expertise to select embryos using physical criteria and observation but the process is time consuming and subjective. Embryoscope and AI technology potentially improves the outcome but is limited to 12 embryos per 3-5 day session and provides only visual information. There is a strong market need for a non-invasive, predictive technology, with high throughput and low cost, that can improve implantation success rate, and reduce the number of cycles. MAP Sciences has developed a diagnostic platform using Matrix Assisted Laser Desorption Ionisation Time of Flight Mass Spectrometry (MALDI-ToF) and advanced protein pattern recognition, using Artificial Intelligence, to diagnose disease states from clinical samples. MAP's research indicates strong correlation for rapid profiling of embryo culture media to select those embryos with highest implantation potential. MAP's ground-breaking technology provides high quality, objective metabolic data for optimal decision making, to radically improve implantation success rate. Key features of the technology are that is not invasive or tissue destructive, is rapid, high throughput, and affordable. Patents are granted in UK. France, Germany, China. Map requires resources to expand data sets and scope by collaborating with IVF clinics to collect samples and data to validate the technology both technically and commercially and create a final product with IVDR -- FDA validation. MAP has secured commitment from instrument manufacturers to ensure rapid introduction and robust support of MAP's software/reagent technology alongside existing and newly introduced machines. A successful project outcome is important clinically, commercially, and from the patient's perspective, emotionally and financially.